Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Production / Operations

Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant(TM) Touch Laser in Canada

By The Northwire Desk — AI Analysis Feb 23, 2026 · 08:00 BHC · 8.37 BAUSCH HEALTH COMPANIES INC.
BHC · Price

Executive Summary

  • Bausch Health’s Solta Medical announced the Canadian launch of the Clear + Brilliant® Touch laser system, approved by Health Canada on May 20 2025.
  • The dual‑wavelength device is now available to Canadian physicians for non‑invasive skin rejuvenation across a broad range of indications.
  • Launch expands Solta’s global footprint and adds a new revenue opportunity within Bausch Health’s aesthetics portfolio.

Key Details

  • Regulatory approval: Health Canada cleared the Clear + Brilliant® Touch system on 20 May 2025.
  • Device description: Dual‑wavelength fractional laser with two handpieces (1440 nm and 1927 nm) offering treatment for wrinkles, dyschromia, pigmentation, skin texture, pore size, and enhanced skin permeability.
  • Market impact: Provides Canadian physicians with an advanced, customizable aesthetic solution; aligns with growing demand for non‑invasive skin rejuvenation in Canada.
  • Corporate statements:
  • Thomas J. Appio, CEO of Bausch Health, highlighted the launch as part of Solta’s global expansion and strong market interest in Canada.
  • Jiny Kim, SVP of Solta Medical, emphasized the significance of bringing the system to Canadian providers and patients.
  • Clinical background: Platform supported by more than 15 clinical studies demonstrating safety and efficacy for early‑sign signs of aging and overall skin improvement.
  • Availability: Device now commercially available in Canada; further information and safety details at ca.clearandbrilliant.com/hcp.

Notable Quotes

“The Solta business continues to expand its global presence through its diverse and well‑established portfolio that supports the growing demand for high‑quality aesthetics solutions,” – Thomas J. Appio, CEO, Bausch Health.

“Expanding the availability of the Clear + Brilliant Touch System into Canada marks a significant step forward for Solta Medical… This launch reinforces Solta's leadership in supporting both providers and patients with technology that delivers safe, effective and customizable results,” – Jiny Kim, Senior Vice President, Solta Medical.

Read the original news release →

More from BAUSCH HEALTH COMPANIES INC.

Jun 09, 2026 · 08:00

Canadian drug plan LOI for PrOKEDI is a steady commercial step, but the stock's -6.5% drift into the print reflects broader pipeline and debt overhangs already discounted.

Regulatory May 28, 2026 · 16:15

Solta Trademark Win Reinforces China Growth Narrative Amidst Elevated Debt Costs and Xifaxan LOE Clock

Production / Operations Apr 29, 2026 · 16:05

BHC Q1 Earnings Mask Pipeline Failure with Core Cash Flow Strength

Earnings Apr 14, 2026 · 08:00

Biafine Launch Fails to Offset Clinical Failure and Debt Burden

Other Feb 23, 2026 · 17:59

Bausch Health launches Clear + Brilliant in Canada

Regulatory Feb 18, 2026 · 16:05

BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS

Earnings